A H Baer1, B A Hoff2, A Srinivasan2, C J Galbán2, S K Mukherji3. 1. From the Department of Radiology (A.H.B., B.A.H., A.S., C.J.G.), University of Michigan Health System, Ann Arbor, Michigan aaronbaer@gmail.com. 2. From the Department of Radiology (A.H.B., B.A.H., A.S., C.J.G.), University of Michigan Health System, Ann Arbor, Michigan. 3. Department of Radiology (S.K.M.), Michigan State University, East Lansing, Michigan.
Abstract
BACKGROUND AND PURPOSE: Estimating changes in the volume transfer constant, normalized area under the contrast-enhancement time curve at 60 seconds, and fractional blood plasma volume by using dynamic contrast-enhanced MR imaging may be useful in predicting tumor response to chemoradiation. We hypothesized that the parametric response map, a voxel-by-voxel analysis of quantitative dynamic contrast-enhanced MR imaging maps, predicts survival in patients with head and neck cancer. MATERIALS AND METHODS: Ten patients with locoregionally advanced head and neck squamous cell carcinoma underwent definitive concurrent chemoradiation therapy. For each patient, dynamic contrast-enhanced MR imaging data were collected before and 2 weeks after treatment initiation. Change in perfusion parameters within the primary tumor volume with time was analyzed by parametric response mapping and by whole-tumor mean percentage change. Outcome was defined as overall survival. The perfusion parameter and metric most predictive of outcome were identified. Overall survival was estimated by the log-rank test and Kaplan-Meier survival curve. RESULTS: The volume transfer constant and normalized area under the contrast-enhancement time curve at 60 seconds were predictive of survival both in parametric response map analysis (volume transfer constant, P = .002; normalized area under the contrast-enhancement time curve at 60 seconds, P = .02) and in the percentage change analysis (volume transfer constant, P = .04; normalized area under the contrast-enhancement time curve at 60 seconds, P = .02). Blood plasma volume predicted survival in neither analysis. CONCLUSIONS: Parametric response mapping of MR perfusion biomarkers could potentially guide treatment modification in patients with predicted treatment failure. Larger studies are needed to determine whether parametric response map analysis or percentage signal change in these perfusion parameters is the stronger predictor of survival.
BACKGROUND AND PURPOSE: Estimating changes in the volume transfer constant, normalized area under the contrast-enhancement time curve at 60 seconds, and fractional blood plasma volume by using dynamic contrast-enhanced MR imaging may be useful in predicting tumor response to chemoradiation. We hypothesized that the parametric response map, a voxel-by-voxel analysis of quantitative dynamic contrast-enhanced MR imaging maps, predicts survival in patients with head and neck cancer. MATERIALS AND METHODS: Ten patients with locoregionally advanced head and neck squamous cell carcinoma underwent definitive concurrent chemoradiation therapy. For each patient, dynamic contrast-enhanced MR imaging data were collected before and 2 weeks after treatment initiation. Change in perfusion parameters within the primary tumor volume with time was analyzed by parametric response mapping and by whole-tumor mean percentage change. Outcome was defined as overall survival. The perfusion parameter and metric most predictive of outcome were identified. Overall survival was estimated by the log-rank test and Kaplan-Meier survival curve. RESULTS: The volume transfer constant and normalized area under the contrast-enhancement time curve at 60 seconds were predictive of survival both in parametric response map analysis (volume transfer constant, P = .002; normalized area under the contrast-enhancement time curve at 60 seconds, P = .02) and in the percentage change analysis (volume transfer constant, P = .04; normalized area under the contrast-enhancement time curve at 60 seconds, P = .02). Blood plasma volume predicted survival in neither analysis. CONCLUSIONS: Parametric response mapping of MR perfusion biomarkers could potentially guide treatment modification in patients with predicted treatment failure. Larger studies are needed to determine whether parametric response map analysis or percentage signal change in these perfusion parameters is the stronger predictor of survival.
Authors: Ashok Srinivasan; Thomas L Chenevert; Ben A Dwamena; Avraham Eisbruch; Kuanwong Watcharotone; James D Myles; Suresh K Mukherji Journal: J Comput Assist Tomogr Date: 2012 Jan-Feb Impact factor: 1.826
Authors: Christina Tsien; Craig J Galbán; Thomas L Chenevert; Timothy D Johnson; Daniel A Hamstra; Pia C Sundgren; Larry Junck; Charles R Meyer; Alnawaz Rehemtulla; Theodore Lawrence; Brian D Ross Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross Journal: Proc Natl Acad Sci U S A Date: 2005-11-02 Impact factor: 11.205
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Kee H Wong; Rafal Panek; Shreerang A Bhide; Christopher M Nutting; Kevin J Harrington; Katie L Newbold Journal: Br J Radiol Date: 2017-03 Impact factor: 3.039
Authors: Ernst S Kooreman; Vivian van Pelt; Marlies E Nowee; Floris Pos; Uulke A van der Heide; Petra J van Houdt Journal: Front Oncol Date: 2022-06-07 Impact factor: 5.738
Authors: Myo Min; Mark T Lee; Peter Lin; Lois Holloway; Dj Wijesekera; Dinesh Gooneratne; Robba Rai; Wei Xuan; Allan Fowler; Dion Forstner; Gary Liney Journal: Br J Radiol Date: 2015-12-09 Impact factor: 3.039
Authors: Kee H Wong; Rafal Panek; Alex Dunlop; Dualta Mcquaid; Angela Riddell; Liam C Welsh; Iain Murray; Dow-Mu Koh; Martin O Leach; Shreerang A Bhide; Christopher M Nutting; Wim J Oyen; Kevin J Harrington; Kate L Newbold Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-21 Impact factor: 9.236